Vesalio appoints CFO and announces company headquarters in Dallas, Texas
Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature
NeVa CLEAR Study results presented at ESMINT: innovative thrombectomy device achieves notable first-pass success and patient outcomes
Primary results from the CLEAR Study were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of the international commercialization of the NeVa™ device.
Vesalio Announces Initial Use of its Uniquely Designed and FDA-approved NeVa VS Device
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
Vesalio appoints VP of U.S. Sales and announces recent publication on NeVa showing impressive first pass rates
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
Vesalio announces EU MDR Certification
MDR certification confirms the company’s commitment of ensuring that their innovative new products meet or exceed these rigorous new standards.
Vesalio announces FDA Approval of the NeVa VS™
NeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture.
Vesalio announces CE Approval for new NeVa NET™
The first integrated clot micro-filtration technology for stroke thrombectomy patients.
Vesalio announces oversubscribed Class A financing
Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round.
Vesalio Announces Completion of Enrollment in its FDA Enabling Stroke Study
Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke.
Vesalio Announces Earl Slee as New Board Observer and Senior Advisor to the Company
As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise.
